Fig. 4
From: Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cancer Antigen-1
CT83 expression by cancer cell lines and tumors. a The frequency (% of tumors that express the antigen) of CT83 expression by different cancer types was assessed. Expression data are derived from TCGA Provisional dataset accessed through cBioportal. Fragments Per Kilobase of transcript per Million mapped reads (FPKM) values > 0 were considered positive. The number of samples per cancer type is indicated in parentheses. b A panel of cancer cell lines was assessed for CT83 expression by qRT-PCR. The y-axis displays CT83 copies per 105 copies of ACTB. This experiment was performed twice with similar results. c The frequency of HPV+ metastatic cancers that express CT83 was assessed by qRT-PCR. The number of samples per cancer type is indicated in parentheses. Experiments were performed twice. d Intratumoral heterogeneity of CT83 expression was assessed by RNA ISH using RNAScope. The tumor type is indicated on the x-axis. The frequency of CT83+ tumor cells was scored by an independent, blinded pathologist. e Sample images of CT83+ tumors by RNAScope are shown. Magnification is 20X. Nuclei were counterstained with DAPI (blue)